# OnCo record cabozantinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/cabozantinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "cabozantinib" ;
  schema:name "Cabozantinib"@en ;
  schema:description "A pill that blocks both blood-vessel growth and the MET escape pathway, used in kidney, liver, thyroid and, since 2025, neuroendocrine cancers."@en ;
  schema:url <https://onco.cc/drugs/cabozantinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cabozantinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q795057> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Cabozantinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule multi-kinase inhibitor (MET, VEGFR2, AXL, RET)" ;
  schema:alternateName "Cabometyx" ;
  onco:approval "US 2012: Medullary thyroid cancer (Cometriq)", "US 2016: Advanced RCC", "US 2019: HCC previously treated with sorafenib", "US 2025: Advanced pancreatic and extra-pancreatic neuroendocrine tumours after prior therapy (CABINET)", "US 2017: First-line advanced RCC (CABOSUN)", "US 2021: First-line advanced RCC with nivolumab (CheckMate 9ER)", "EU 2014: Cometriq for medullary thyroid cancer; 21 Mar 2014. Cabometyx (RCC) Sep 2016" ;
  onco:cancers <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/hcc-advanced/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/neuroendocrine/>, <https://onco.cc/cancers/thyroid/>, <https://onco.cc/cancers/medullary-thyroid-cancer/>, <https://onco.cc/cancers/clear-cell-rcc/>, <https://onco.cc/cancers/papillary-rcc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/antiangiogenic/> ;
  onco:targets <https://onco.cc/targets/met/>, <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/ret/> ;
  onco:companies <https://onco.cc/companies/exelixis/>, <https://onco.cc/companies/ipsen/> ;
  onco:trials <https://onco.cc/trials/celestial/>, <https://onco.cc/trials/cabinet/>, <https://onco.cc/trials/nct03755791/>, <https://onco.cc/trials/nct04446117/>, <https://onco.cc/trials/nct03690388/>, <https://onco.cc/trials/nct07011719/>, <https://onco.cc/trials/nct03634540/>, <https://onco.cc/trials/nct07293351/>, <https://onco.cc/trials/nct03899155/>, <https://onco.cc/trials/nct04586231/>, <https://onco.cc/trials/nct07405164/>, <https://onco.cc/trials/checkmate-9er/>, <https://onco.cc/trials/cosmic-313/>, <https://onco.cc/trials/contact-03/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-exam-cabozantinib-mtc-elisei-jco-2013/>, <https://onco.cc/key-papers/paper-papmet-pal-lancet-2021/> .